New version of drug discovery support AI “Cascade Eye” announced

Home » corporate » News » 2023 » New version of drug discovery support AI “Cascade Eye” announced
2023.02.20 Press release

--To the press -

New version of drug discovery support AI “Cascade Eye” announced

Added CSV output function for gene list, smooth information sharing

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter: FRONTEO) has announced the drug discovery support AI "Cascade Eye ver. 1.4".

 Cascade Eye analyzes article information and medical information using FRONTEO's natural language analysis AI engine "Concept Encoder (trademark: conceptencoder, reading: concept encoder)", and a network of molecules and genes related to the disease that you want to analyze. is an AI system that displays in the form of a pathway map (a route diagram that shows relationships).In addition to promoting the selection of new drug discovery targets and the efficiency of drug repositioning (diversion of existing drugs to other diseases) research, drug discovery analysis that is not influenced by researcher's bias is evaluated. Since its release in 2020, it has been adopted by pharmaceutical companies, research institutions, and educational institutions.

 In Cascade Eye ver. 1.4, a CSV output function for gene lists has been added, which was requested by many users.This function downloads the gene list as a CSV file by pressing the "CSV button" after generating the network.In addition to the name of each gene, the starting point gene and the ending point gene of the network are described as "Causality Gene" and "Responsive Gene", respectively.This will make it easier for researchers to share gene relationship information, which is the analysis result, with each other.In addition, operability such as gene search has been improved.

 


Press the "CSV button" to download the gene list as a CSV file

 FRONTEO will contribute to DX (digital transformation) of drug discovery research, promotion of efficiency, and improvement of medical quality through research and development of systems that utilize in-house developed AI, which has strengths in natural language processing.


■ About Cascade Eye
 URL:https://lifescience.fronteo.com/aidiscovery/cascade-eye/
"Cascade Eye" uses FRONTEO's natural language analysis AI engine "Concept Encoder" to analyze papers and medical information, and pathway maps (path maps showing relevance) of molecules and genes related to the disease to be analyzed. It is an AI system that displays in the form of).It visualizes the relationships between molecules and genes, and supports a significant improvement in the efficiency of the target search process in drug discovery research. Since AI comprehensively searches a huge amount of information that cannot be read by humans, it is possible to discover new drug discovery targets and diversion of existing drugs to other diseases without being influenced by researcher bias. It enables drug discovery approaches that were difficult with conventional methods, such as identification of unknown biomarkers.

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

*FRONTEO, KIBIT, conceptencoder, Looca Cross, and Cascade Eye are registered trademarks of FRONTEO in Japan.

 

<Contact for inquiries from the press>
PR Department, FRONTEO, Inc.
Email: pr_contact@fronteo.com

<Contact for inquiries regarding the life science AI business>
Life Science AI Business Department, FRONTEO, Inc.
https://lifescience.fronteo.com/contact